Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

The role of IGFBP-3 as a potential pathophysiologic target or biomarker in chronic liver disease

ABSTRACT: The role of IGFBP-3 as a potential pathophysiologic target or biomarker in chronic liver disease

PROVIDER: PRJNA637221 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR11854548_1.fastq.gz	Fastqsanger.gz
	SRR11854548_2.fastq.gz	Fastqsanger.gz
	SRR11854549_1.fastq.gz	Fastqsanger.gz
	SRR11854549_2.fastq.gz	Fastqsanger.gz
	SRR11854550_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 24

Similar Datasets

Extracellular microRNA: Novel Biomarker and Potential Therapeutic Target in Trauma

Project description:Extracellular microRNA: Novel Biomarker and Potential Therapeutic Target in Trauma

| PRJNA925146 | ENA

The role of IGFBP-3 as a potential pathophysiologic target or biomarker in chronic liver disease

Project description:This SuperSeries is composed of the SubSeries listed below.

2020-06-05 | GSE151771 | GEO

RNA-seq from human hepatic stellate cells treated with TGF-β

Project description:Background and Aims: Transforming growth factor (TGF-β) induced activation of quiescent hepatic stellate cells (HSC) and their transformation to myofibroblasts is a key event in liver fibrosis and portal hypertension. GIPC (also referred to as synectin) is a downstream signal activation molecule of TGF-β and other receptors. In this study, we sought to identify novel genes targeted by TGF-β and GIPC and elucidate if and how they may contribute to liver fibrosis. Methods and Results: We performed sequential mRNA sequencing analysis on TGF-β stimulated HSC and then on TGF-β-stimulated HSC in presence and absence of GIPC knockdown. IGFBP-3, an insulin growth factor transport protein, emerged as a top activation target of both TGF-β and GIPC, which was confirmed by qPCR, ELISA and Western blot (WB) analysis. Targeted chromatin immunoprecipitation (ChIP) revealed that GIPC increases the histone 3 lysine 27 (H3K27) acetylation activating mark and concurrently decreases the H3K27 inhibitory trimethylation (H3K27m3) mark providing an epigenetic correlate to the gene regulation changes. In vivo, global knockout of IGFBP-3 mice resulted in attenuation of HSC activation markers and attenuation of portal pressure in response to chronic liver injury models. Analysis of serum levels from cirrhotic patients also showed IGFBP-3 increase of more than 2-fold compared to healthy controls. Finally, in vitro mechanism studies revealed that IGFBP-3 promotes HSC migration through integrin dependent phosphorylation of AKT. Conclusion: TGF-β upregulates IGFBP-3 through GIPC leading to increased HSC migration in vitro and promotes portal hypertension in vivo. These studies support the role of IGFBP-3 as a potential pathophysiologic target or biomarker in chronic liver disease.

2020-05-28 | GSE151251 | GEO

RNA-seq from human hepatic stellate cells treated with GIPC shRNA reveals contribution of GIPC to hepatic fibrosis

2020-05-28 | GSE151250 | GEO

Extracellular vesicle miRNA-21 is a potential biomarker for predicting chronic lung disease in premature infants

Project description:Extracellular vesicle miRNA-21 is a potential biomarker for predicting chronic lung disease in premature infants

| PRJNA531425 | ENA

Quantitative Proteomic Analysis of Plasma Samples from Chronic Hepatitis B and Chronic Liver Failure Patients for Biomarker Discovery

Project description:Hepatitis B virus (HBV)-associated acute on chronic liver failure (HBV-ACLF), characterized by an acute deterioration of liver function in the patients with chronic hepatitis B (CHB), is lack of predicting biomarkers for prognosis. To explore potential biomarkers of HBV-ACLF for clinical applications, immuno-depletion of high-abundance plasma proteins followed by iTRAQ-based quantitative proteomic approach was employed to analyze plasma samples from 20 healthy control people, 20 CHB patients and 20 HBV-ACLF patients, respectively. As a result, a total of 427 proteins were identified and quantified from these samples, and 42 proteins were differentially expressed in HBV-ACLF patients as compared to both CHB patients and healthy controls. According to bioinformatics analysis results, 6 proteins related to immune response (MMR), inflammatory response (OPN, HPX), blood coagulation (ATIII) and lipid metabolism (APO-CII, GP73) were selected as biomarker candidates. Further ELISA analysis confirmed the significant up-regulation of GP73, MMR, OPN and down-regulation of ATIII, HPX, APO-CII in HBV-ACLF plasma samples (p<0.01). Moreover, receiver operating characteristic (ROC) curve analysis revealed high diagnostic value of these candidates in assessing HBV-ACLF. In conclusion, present quantitative proteomic study identified 6 novel HBV-ACLF biomarker candidates and might provide fundamental information for development of HBV-ACLF biomarker.

2018-10-23 | PXD007975 | Pride

Plasma circulating MiRNAs: a new potential biomarker for prostate cancer diagnosis.

Project description:Plasma circulating MiRNAs: a new potential biomarker for prostate cancer diagnosis.

| PRJNA484173 | ENA

hsa_circ_0007841: A novel potential biomarker and drug resistance for multiple myeloma

Project description:hsa_circ_0007841: A novel potential biomarker and drug resistance for multiple myeloma

| PRJNA549859 | ENA

Oral cancer metastatic gene expression profiling: Identification of novel potential biomarker

Project description:Oral cancer metastatic gene expression profiling: Identification of novel potential biomarker

| PRJNA606584 | ENA

Nuclear pCHK1 as a potential biomarker of increased sensitivity to ATR inhibition

Project description:Nuclear pCHK1 as a potential biomarker of increased sensitivity to ATR inhibition